Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate

OBJECTIVE: To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept. METHODS: In this phase IIIb double-blind, double-dummy, 6-month study, patients with rheumatoid arthritis (RA) and inadequate responses to methotrexate were randomized to receive 125 mg SC abatacept on...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, M C, Covarrubias, A, Leon, G, Mysler, E, Keiserman, M, Valente, R, Nash, P, Simon-Campos, J A, Porawska, W, Box, J, Legerton, C, Nasonov, E, Durez, P, Aranda, R, Pappu, R, Delaet, I, Teng, J, Alten, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2011
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229984/
https://www.ncbi.nlm.nih.gov/pubmed/21618201
http://dx.doi.org/10.1002/art.30463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229984/
https://www.ncbi.nlm.nih.gov/pubmed/21618201
http://dx.doi.org/10.1002/art.30463

Ejemplares similares